BioCina, an Australia-based contract development and manufacturing organisation (CDMO), announced on Tuesday that it has named Mark W. Womack as its new CEO.
In the new role, Womack will be responsible for the continued growth, commercial strategy and organisational culture of BioCina.
Womack has 30 years of experience across executive leadership, management consulting and CDMO commercial operations. He has served as CEO of KBI Biopharma and Selexis SA. He has also held the position of CEO and managing director of Stelis Biopharma and chief business officer at AGC Biologics. He started his career with over ten years of service in the US Navy.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer